536 related articles for article (PubMed ID: 18240279)
1. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease.
Walkiewicz D; Werlin SL; Fish D; Scanlon M; Hanaway P; Kugathasan S
Inflamm Bowel Dis; 2008 May; 14(5):669-73. PubMed ID: 18240279
[TBL] [Abstract][Full Text] [Related]
2. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
3. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
4. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
5. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
Molander P; Färkkilä M; Ristimäki A; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
J Crohns Colitis; 2015 Jan; 9(1):33-40. PubMed ID: 25052347
[TBL] [Abstract][Full Text] [Related]
6. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases.
Diamanti A; Colistro F; Basso MS; Papadatou B; Francalanci P; Bracci F; Muraca M; Knafelz D; De Angelis P; Castro M
Inflamm Bowel Dis; 2008 Sep; 14(9):1229-35. PubMed ID: 18398894
[TBL] [Abstract][Full Text] [Related]
7. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
8. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease.
Julsgaard M; Hvas CL; Gearry RB; Vestergaard T; Fallingborg J; Svenningsen L; Kjeldsen J; Sparrow MP; Wildt S; Kelsen J; Bell SJ
Inflamm Bowel Dis; 2017 Jul; 23(7):1240-1246. PubMed ID: 28498159
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity.
Lee YW; Lee KM; Lee JM; Chung YY; Kim DB; Kim YJ; Chung WC; Paik CN
Korean J Intern Med; 2019 Jan; 34(1):72-80. PubMed ID: 29347813
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
11. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies.
Mao R; Xiao YL; Gao X; Chen BL; He Y; Yang L; Hu PJ; Chen MH
Inflamm Bowel Dis; 2012 Oct; 18(10):1894-9. PubMed ID: 22238138
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease.
Aomatsu T; Yoden A; Matsumoto K; Kimura E; Inoue K; Andoh A; Tamai H
Dig Dis Sci; 2011 Aug; 56(8):2372-7. PubMed ID: 21394462
[TBL] [Abstract][Full Text] [Related]
13. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
Yang Z; Clark N; Park KT
Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
[TBL] [Abstract][Full Text] [Related]
15. Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.
Dolinšek J; Rižnik P; Sabath L; Mičetić-Turk D
Wien Klin Wochenschr; 2016 Apr; 128(7-8):253-9. PubMed ID: 26659704
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
17. Fecal calprotectin as a promising marker of inflammatory diseases.
Paduchova Z; Durackova Z
Bratisl Lek Listy; 2009; 110(10):598-602. PubMed ID: 20017448
[TBL] [Abstract][Full Text] [Related]
18. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.
Molander P; af Björkesten CG; Mustonen H; Haapamäki J; Vauhkonen M; Kolho KL; Färkkilä M; Sipponen T
Inflamm Bowel Dis; 2012 Nov; 18(11):2011-7. PubMed ID: 22223566
[TBL] [Abstract][Full Text] [Related]
19. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
20. Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease.
Aomatsu T; Imaeda H; Matsumoto K; Kimura E; Yoden A; Tamai H; Fujiyama Y; Mizoguchi E; Andoh A
Aliment Pharmacol Ther; 2011 Oct; 34(8):941-8. PubMed ID: 21848856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
